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We have reported the clinical and biochemical findings in juvenile visceral steatosis (jvs) mice with systemic arnitine deficiency. This paper is the 
first report about cardiomyopathy injvs mice. Adult jvs mice (at the age of 2 3 months) show cardiac hypertrophy which is caused by enlargement 
of the cardiac muscle cell associated with increases of non-collagen protein and DNA content. Carnitine administration (2 mg/head, twice a day, 
from 1 month of age) significantly suppresses the cardiac hypertrophy, showing that carnitine deficiency plays an important role in the development 
of the cardiac hypertrophy. The discovery of cardiac hypertrophy in carnitine-deficient jvs mice will lead to clarification of the pathophysiology 
of cardiomyopathy in systemic arnitine deficiency in human beings. 
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1. INTRODUCTION 
In 1988, Koizumi et al. reported a C3H-H-2 ° strain 
of mouse autosomal-recessively associated with mi- 
crovesicular fatty infiltration of viscera [1]. The mice 
were later named juvenile visceral steatosis 0vs) mice 
[2]. Jvs mice have severe lipid accumulation i the liver, 
hypoglycemia, hyperammonemia and growth retarda- 
tion. The lipid accumulation is found within 5 days of 
birth, but the hypoglycemia, hyperammonemia and 
growth retardation appear 3 weeks after birth [1,2]. Jvs 
mice are systemically deficient in carnitine [3]. Recently, 
we found that the primary defect of jvs mice is in the 
reabsorptional system for carnitine in the kidney 
(Horiuchi et al., manuscript in preparation). 
Many cases of human systemic arnitine deficiency 
have been reported [4-7]. Recently, more than 20 cases 
of human systemic carnitine deficiency have been 
shown to have a defect of carnitine uptake into cultured 
fibroblasts and are suspected to have impaired renal 
conservation of carnitine. In these patients, the most 
common clinical manifestation is cardiomyopathy 
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[5-7]. Unexpectedly, there have been only a few reports 
that give the detail nformations about the cardiomy- 
opathy. In clinical and pathological nalysis, congestive 
heart failure, accumulations of triglycerides and in- 
creases of mitochondria have been only described [8,9]. 
We found that jvs mice suffer from cardiac hypertro- 
phy associated with increases of cardiac proteins (cy- 
tosolic and mitochondrial proteins) and DNA content, 
but no recognizable triglyceride deposition. The sup- 
pression of the development of cardiac hypertrophy by 
carnitine administration shows the strong interrelation- 
ship between carnitine deficiency and cardiac hypertro- 
phy in jvs mice. Therefore, we report here that jvs mice 
are a very valuable animal model for studying the pa- 
thophysiology in cardiomyopathy in systemic arnitine 
deficiency. 
2. MATERIALS AND METHODS 
2.1. Animals and carnitine administration 
Jvs mice were accidentally found in C3H-H-2 ° strain mice at Ka- 
nazawa University, Japan, in 1985 [1]. The unusually swollen whitish 
fatty liver is recognized through the abdominal wall 5 days after birth, 
at the latest, in homozygous mutants 0vs/jvs). Under our conditions 
for keeping jvs mice at Kagoshima University, about 50% of homozy- 
gous mutants die at 1 month of age, and almost all homozygous 
mutants die at 34  months of age without any treatment. We obtained 
three genetic types of the mice by the following procedures: homozy- 
gous mutants 0vs/jvs) and heterozygous mice (+/jvs) were produced 
by mating carnitine-treated homozygous mutant males with heterozy- 
gous females. Because heterozygous mice have no fatty liver, it is easy 
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to discriminate between homozygous mutants andheterozygous mice. 
Homozygous controls (+/+) were produced by mating homozygous 
controls with each other. Carnitine treatment was carried out to main- 
tain surviving homozygous males for mating as reported previously 
[10]. In the present work, we used the surviving homozygous mutants 
without any treatment, except for those in Table III. The homozygous 
mutants and homozygous control mice used in Table III were injected 
with 5,umol of L-carnitine from 11 days after birth till 20 days, because 
this treatment increases the survival rate. The carnitine-treated ho- 
mozygous mutants in Table III were additionally injected with 10 
/lmol of L-carnitine twice a day from 30 days until 90 days after birth. 
2.2. Quantification of protein, DNA content and enzyme activities in 
heart 
The whole heart was homogenized with 9 vols. of 0.02 M NaHCO 3. 
The homogenate was treated with 3 vols. of 0.1 N NaOH to precipitate 
collagen and elastin according to the modified Lilienthal procedure 
[11]. The concentration of non-collagen protein in the supernatant 
extracted by alkali treatment was determined by Lowry's method [12]. 
The DNA concentration i the homogenates was assayed by using 
mithramycin i tercalated with double strands of DNA [13]. Alterna- 
tively, DNA was extracted from the heart with phenol/chloroform 
after digestion with proteinase K [14], and the concentration of DNA 
was estimated by using an extinction coefficient (1 OD260n m = 50 pg/ml 
of DNA). Aldolase activity for FBP as a substrate [15], GOT [16], and 
SDH [17] was assayed by the published procedures. We discrimina- 
tively assayed s-GOT and m-GOT activities by using an m-GOT assay 
kit (Eiken Kagaku Co., Tokyo). The homogenates were treated with 
anti-s-GOT antibody (swine) for 35 min at room temperature, and 
centrifuged at 3,000 rpm for 5 min. The GOT activity in the superna- 
tant was determined as m-GOT activity. S-GOT was calculated as 
total GOT activity minus m-GOT activity. Serum carnitine was meas- 
ured by using the isotope method [18]. 
2.3. Statistics 
Data were analysed statistically by the unpaired t-test with the level 
of significance set at P < 0.05. 
2.4. Pathological examination 
Mice were sacrificed at 3 months of age. The fixation was carried 
out by 10% (v/v) formalin in 0.2 M sodium phosphate buffer (pH 7.4) 
for microscopic examination, a d the specimens were stained with 
hematoxylin-eosin. 
3. RESULTS 
Table I shows that the wet weight of the adult heart 
and the ratio of heart weight to body weight in homozy- 
gous mutants 0vs/jvs) were about twice as high as those 
in heterozygous (+/jvs) and homozygous controls (+/+). 
There was no significant difference between homozy- 
gous controls and heterozygotes in heart weight and in 
the ratio of heart weight to body weight. The increase 
in heart weight was associated with increases in non- 
collagen protein content and DNA content per heart. 
The increase of total DNA content in jvs mice heart was 
reexamined by a determination fextracted DNA. Con- 
trols and homozygous mutants showed 78 + 4 and 
202 + 58/.tg/heart, respectively. There was no signifi- 
cant difference in the ratios of heart weight to body 
weight between male and female homozygous mutants 
(data not shown). 
As shown in Fig. 1, microscopic examination 
revealed an increase in cardiac cell volume with defor- 
mation and enlargement of the nucleus and little vacu- 
olation in the cytoplasms in homozygous mutants. Elec- 
tronmicroscopic examination showed that there was no 
significant change in the size and number of lipid drop- 
lets, and that the number of mitochondria was larger in 
homozygous mutants than in controls (data not shown). 
In homozygous mutants, non-collagen protein con- 
tent was 2.5 times the control value (Table I). This 
increase was accompanied by increases not only in cy- 
tosolic enzymes, but also in mitochondrial enzymes as 
given in Table II. The increase of total enzyme activity 
per heart was about 2-fold in cytosolic enzymes (al- 
dolase and s-GOT) and 3-fold in mitochondrial en- 
zymes (m-GOT and SDH). These results indicate that 
homozygous mutants uffer from cardiac hypertrophy 
associated with increased cardiac protein content in- 
cluding cytosolic and mitochondrial proteins. 
Since homozygous mutant mice were deficient in car- 
nitine in the blood as shown in Table I, we assessed the 
effect of carnitine administration on cardiac hypertro- 
phy in jvs mice (Table III). Mice were injected with 
L-carnitine (5 ~tmol once a day) from 11 days to 20 days 
after birth, and again injected (10 ¢tmol twice a day) 
from 1 month to the time of sacrifice (3 months). There 
were no significant differences in heart weight to body 
Table I 
Heart weight, body weight, protein content, DNA content, and serum carnitine in control (+/+), heterozygotes (+/jvs), and homozygous mutants 
0vs/jvs) at 2 3 months of age 
H.W. B.W. H.W./B.W. NCP/heart DNA/heart Serum carnitine 
(g) (g) (%) (mg) (~g) (nmol/ml) 
Control 
(+/+) 0.11 -+ 0.02 21.6 _+ 3.3 0.51 _+ 0.03 10.7 + 1.8 230 _+ 70 45.7 _+ 9.2 
Heterozygotes 
(+/jvs) 0.10 + 0.01 23.7 _+ 4.7 0.43 + 0.06 N.D. N.D. 37.1 + 5.9 
Homozygous mutants 
0vs/jvs) 0.23 + 0.03** 20.8 + 2.6 1.12 _+ 0.12"* 24.8 _+ 3.7** 390 _+ 100" 2.3 +_ 0.8** 
5 mice without carnitine treatment were used for each experiment from 70 days to 90 days after birth. Values are expressed as mean + S.D. 
Statistically significant differences between homozygous mutants and controls: *P < 0.05; **P < 0.01. N.D., not determined. H.W., heart wet 
weight; B.W., body weight; NCP, non-collagen protein. 
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(+/+) Ovs/jvs) 
Fig. 1. Microscopic examination of hearts from control (+/+, left panels), and homozygous mutant Ovs/jvs, right panels) mice at 3 months ofage. 
The upper part is longitudinal section and the lower part is cross ection. Hematoxylin-eosin stain, x 300. 
weight between homozygous mutants with and without 
short-term carnitine administration (from 11 days to 20 
days after birth, Table I and Table III). On the other 
hand, long-term carnitine administered jvs mice (from 
1 month to 3 months) showed significantly smaller heart 
weight and heart weight to body weight ratio than the 
homozygous mutants without additional long-term ad- 
ministration, and there was no significant difference in 
the ratios of heart weight to body weight between the 
long-term carnitine administered jvs mice and homozy- 
gous controls. 
4. DISCUSSION 
We found that jvs mice suffered from abdominal as- 
cites at 34  months of age associated with congestive 
liver and enlargement of the heart. These conditions 
were diagnosed as heart failure. In order to understand 
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Table II 
Cytosolic and mitochondrial enzyme activities in control (+/+) and homozygous mutant Ovs/jvs) mice at 2 3 months of age 
Cytosolic enzymes Mitochondrial enzymes 
Aldolase (FBP) s-GOT m-GOT SDH 
U/mg NCP U/heart U/mg NCP U/heart U/mg NCP U/heart U/mg NCP U/heart 
Control (+/+) 0.092 + 0.027 0.93 _+ 0.28 0.68 +0.05 7.0 + 1.2 0.53 + 0.03 5.5 _+ 1.0 73 + 16 0.75 + 0.23 
Homozygous 0.076 + 0.022 1.91 _+ 0.48** 0.63 +0.04 16.2 + 3.3** 0.55 + 0.07 14.1 + 3.3** 94 + 7* 2.4 + 0.5** 
mutants (jvs/jvs) 
4 mice were used for the experiments 70 days to 90 days after birth. Statistically significant differences between groups: *P < 0.05; **P < O.Ot. 
the pathophysiology of  heart failure, we analysed the 
heart of  jvs mice without abdominal ascites at 2-3 
months of  age, and found a remarkable increase in heart 
weight. This is probably caused by an increase in car- 
diac cell size associated with non-collagen protein con- 
tent (Table I), without recognizable triglyceride deposi- 
tion (Fig. 1). Although the DNA content was about 
twice that of  homozygous controls, cardiac cell number 
did not seem to be increased in the pathological exami- 
nation (Fig. 1). Therefore, we assume that the increase 
in DNA content is caused by stimulation of  DNA repli- 
cation without cell division, and that the increase in 
heart weight is mainly caused by cardiac cell hypertro- 
phy associated with the increase of  cytosolic and mito- 
chondrial proteins (Table II). 
As shown in Table II I, this cardiac cell hypertrophy 
is prevented by long-term carnitine administration. 
Heterozygous mutants with sufficient carnitine concen- 
tration in the serum do not suffer from cardiac hy- 
pertrophy (Table I). Our previous report [10] and the 
present study show that carnitine deficiency plays an 
important role in the development of  the pathological 
conditions of  the liver and the heart in jvs mice. Car- 
nitine deficiency causes an abnormality in organ-spe- 
cific gene expression in the liver [19,20] and an abnor- 
mality in cell growth (hypertrophy) in the heart. How 
carnitine deficiency causes these various abnormalities 
in the heart and liver is a matter of  great interest. Re- 
cently, Tomomura et al. [21] reported that the expres- 
sion of  the proto-oncogenes, c-jun and c-fos, is in- 
creased in the liver of  homozygous mutants 0vs/jvs). 
The relationship between carnitine deficiency and the 
induction of  the proto-oncogenes has not yet been eluci- 
dated. On the other hand, there are some reports about 
the induction of  these proto-oncogenes in cardiac cells 
by factors which are related to cardiac hypertrophy, 
such as pressure overload [22], mechanical load [23], 
and fl-adrenergic stimulation [24]. Therefore, in order 
to understand the pathophysiology of  jvs mice, it is 
necessary to analyse the proto-oncogenes in the cardiac 
cells. 
To our knowledge, 3 kinds of  animal models for car- 
diac hypertrophy have been reported: spontaneously 
hypertensive rat (SHR) [25], syrian hamster with cardi- 
omyopathy [26], and c-myc transgenic mice [27]. Al- 
though the mechanism causing cardiac hypertrophy in 
the former two animals is suspected to be in the abnor- 
mality of  the cardiac cellular membrane [28,29], this is 
still not clear. The c-myc transgenic mice show cardiac 
hyperplasty, rather than cardiac hypertrophy. In any 
case, they are valuable animal models for cardiac ab- 
normality in human beings. Our study revealed that jvs 
Table III 
Effect of carnitine administration on cardiac hypertrophy in jvs mice 
Mouse Carnitine treatment B.W. H.W. H.W./B.W. 
(g) (g) (%) 
11 20 days 30-90 days 
jvs/jvs 
(6)~ (+)6 (-) 25.0 + 1.6 0.27 + 0.05 1.07 + 0.14 
jvs/jvs ] ** 
(4) (+) (+) 25.0 -+ 2.7 0.15 + 0.03 0.59 -+ 0.13 
+[+ ] * 
(4) (+) (-) 23.5 __+ 1.6 0.10 + 0.01 0.45 +- 0.03 
**  
]NS 
Numbers in parentheses indicate number of animals used for experiments. 
b(+) and (-) indicate with and without carnitine administration, espectively. 
Values are expressed as mean + S.D. Statistically significant differences between groups: *P < 0.05; **P < 0.01. NS, not significant. 
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mice with systemic carni t ine def ic iency suffer f rom re- 
markab le  card iac  hypert rophy,  and that  the card iac  hy- 
per t rophy  is strongly related to carn i t ine deficiency be- 
cause it is t reatable by carn i t ine admin is t ra t ion  (Table 
I I I).  Therefore ,  jvs mice are a va luab le  an imal  mode l  to 
clar i fy the mechan ism of  card iac  abnormal i ty  in sys- 
temic  carni t ine def ic iency in humans .  
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